MedTrace Logo

A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate

NCT03488719 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2024-02-09

Study results available
· View outcomes & findings →

Summary

A Phase 1 Study to Examine Pharmacodynamic Interaction Between Tesofensine and Metoprolol on 24-hours Mean Heart Rate

Conditions

  • Phase 1

Interventions

DRUG

Metoprolol Succinate 25 MG

A single dose of 25 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.

DRUG

Metoprolol Succinate 50 MG

A single dose of 50 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21 approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.

DRUG

Metoprolol Succinate 100 MG

A single dose of 100 mg metoprolol ER in the morning of Day 15, Day 18 or Day 21, approximately 30 minutes after start of a standard breakfast and together with the tesofensine dose.

Sponsors & Collaborators

  • Saniona

    lead INDUSTRY

Principal Investigators

  • Kim Krogsgaard, MD, DMSc · Saniona

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-11
Primary Completion
2019-06-06
Completion
2019-06-06

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03488719 on ClinicalTrials.gov